This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.
Stocks in play: Microbix Biosystems Inc.
Announces that the contract development and manufacturing organization engaged by its funding and commercialization partner, Sequel Pharma, LLC, has modernized production methods for the active ingredient of Kinlytic® urokinase, a biologic for dissolving blood clots. Microbix Biosystems Inc. shares T.MBX are trading up $0.02 at $0.25.
